IXI - Ticker AI Digest

IXICO PLC 📰 1
7.19 | Today 0.91%
TradingFloor AI GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
IXICO PLC in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, crunch, and the deeper desks.
IXI Data 2026-04-21 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (IXI) 1
IXI 06:01
IXICO PLC
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
IXICO PLC reports strong growth in H1 2026, with revenues up 23% to £3.9 million, gross margin increasing to 53%, and order book rising 38% to £18.1 million. EBITDA loss narrowed to £0.5 million, reflecting strategic investments in growth. A £10 million capital raise supports the Tech Bio strategy to enhance the IXITM platforms integration with CROs and healthcare providers. Interim results will be released on May 19, 2026, with a live presentation for shareholders.
MetricH1 2026H1 2025Change
Revenues (£ million)3.93.2+23%
Gross Margin (%)53%50%+3%
Order Book (£ million)18.113.1+38%
EBITDA Loss (£ million)-0.5-0.7-28.6%
Cash Position (£ million)1.75.0-66%
Capital Raise (£ million)10.0 (net: 9.4)N/AN/A
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 3
IXI 12:15
IXICO PLC
Result of Retail Offer
IXI 06:02
IXICO PLC
Retail Offer
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
IXICO PLC announces a retail offer of up to 6,250,000 new ordinary shares at 8 pence each, alongside a £10 million fundraising through placings and a subscription. The retail offer, open to existing UK shareholders, aims to raise £0.5 million, with proceeds directed towards platform automation, analysis pipeline differentiation, and corporate development. The offer runs from March 31 to April 7, 2026, with admission to trading expected on April 17, 2026, subject to shareholder approval. The issue price represents a 1.6% premium to the previous closing price, and the offer is conditional on shareholder resolutions and completion of the first placing. Investors are warned of risks, including capital loss and dilution, and should consult independent advice.
Premium Placing
IXI 06:01
IXICO PLC
Placings and Subscription
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
IXICO plc, a global leader in neuroscience imaging and biomarker analytics, announced a proposed fundraising of up to £10.5 million through a combination of placings, subscription, and a retail offer. The funds will be used to develop the IXI™ Platform, invest in staff, and pursue FDA approval for their software as a medical device. The fundraising includes a first placing of £2.8 million, a subscription of £0.1 million, a second placing of £7.1 million, and a retail offer of up to £0.5 million. The company will hold a general meeting on April 16, 2026, to approve the necessary resolutions for the fundraising. The issue price for the new shares is 8 pence, representing a 1.6% premium to the previous closing price. The company aims to accelerate growth by expanding its addressable market through a TechBio model, enabling third-party licensing and integration of its technology.
Premium Placing
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 2
IXI 06:01
IXICO PLC
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
IXICO PLC reports strong growth in H1 2026, with revenues up 23% to £3.9 million, gross margin increasing to 53%, and order book rising 38% to £18.1 million. EBITDA loss narrowed to £0.5 million, reflecting strategic investments in growth. A £10 million capital raise supports the Tech Bio strategy to enhance the IXITM platforms integration with CROs and healthcare providers. Interim results will be released on May 19, 2026, with a live presentation for shareholders.
MetricH1 2026H1 2025Change
Revenues (£ million)3.93.2+23%
Gross Margin (%)53%50%+3%
Order Book (£ million)18.113.1+38%
EBITDA Loss (£ million)-0.5-0.7-28.6%
Cash Position (£ million)1.75.0-66%
Capital Raise (£ million)10.0 (net: 9.4)N/AN/A
IXI 11:02
IXICO PLC
Result of GM and Update on Issue of Equity
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 6
IXI 06:01
IXICO PLC
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
IXICO PLC reports strong growth in H1 2026, with revenues up 23% to £3.9 million, gross margin increasing to 53%, and order book rising 38% to £18.1 million. EBITDA loss narrowed to £0.5 million, reflecting strategic investments in growth. A £10 million capital raise supports the Tech Bio strategy to enhance the IXITM platforms integration with CROs and healthcare providers. Interim results will be released on May 19, 2026, with a live presentation for shareholders.
MetricH1 2026H1 2025Change
Revenues (£ million)3.93.2+23%
Gross Margin (%)53%50%+3%
Order Book (£ million)18.113.1+38%
EBITDA Loss (£ million)-0.5-0.7-28.6%
Cash Position (£ million)1.75.0-66%
Capital Raise (£ million)10.0 (net: 9.4)N/AN/A
IXI 11:02
IXICO PLC
Result of GM and Update on Issue of Equity
IXI 12:15
IXICO PLC
Result of Retail Offer
IXI 06:02
IXICO PLC
Retail Offer
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
IXICO PLC announces a retail offer of up to 6,250,000 new ordinary shares at 8 pence each, alongside a £10 million fundraising through placings and a subscription. The retail offer, open to existing UK shareholders, aims to raise £0.5 million, with proceeds directed towards platform automation, analysis pipeline differentiation, and corporate development. The offer runs from March 31 to April 7, 2026, with admission to trading expected on April 17, 2026, subject to shareholder approval. The issue price represents a 1.6% premium to the previous closing price, and the offer is conditional on shareholder resolutions and completion of the first placing. Investors are warned of risks, including capital loss and dilution, and should consult independent advice.
Premium Placing
IXI 06:01
IXICO PLC
Placings and Subscription
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
IXICO plc, a global leader in neuroscience imaging and biomarker analytics, announced a proposed fundraising of up to £10.5 million through a combination of placings, subscription, and a retail offer. The funds will be used to develop the IXI™ Platform, invest in staff, and pursue FDA approval for their software as a medical device. The fundraising includes a first placing of £2.8 million, a subscription of £0.1 million, a second placing of £7.1 million, and a retail offer of up to £0.5 million. The company will hold a general meeting on April 16, 2026, to approve the necessary resolutions for the fundraising. The issue price for the new shares is 8 pence, representing a 1.6% premium to the previous closing price. The company aims to accelerate growth by expanding its addressable market through a TechBio model, enabling third-party licensing and integration of its technology.
Premium Placing
IXI 06:01
IXICO PLC
Collaboration with Medidata

AI Crunch

Single-Ticker AI Crunch
IXI signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for IXICO PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full IXI AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for IXI on 2026-04-21.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
6.6M
Enterprise Value
8.7M
Public Float
37.7
Broker Target
26
Shares Out
92.7M
Long Interest
100
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
GB00BFXR4C20
Market
LSE - AIM
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for IXI.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-04-21 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
IXICO PLC has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2025-12-02
Net Debt
-3.4M
Cash
3.5M
EPS
-0.02
Net Income
-1.7M
Revenue
6.5M
Enterprise Value
8.7M
Trailing PE
-
Forward PE
47.3934
Price Sales TTM
1.0105
Price Book MRQ
0.5625
EV Revenue
0.4966
EV EBITDA
3.3805
Financial Forecastist

Mixed financial engine

Revenue is slipping -3.9% against the prior comparable period. Net margin is compressing by 7.8 pts. Net debt is coming down +7.8%.

Revenue -3.9% Net Income +53.0% FCF -8.3% Current Ratio 3.03x Forward Rev 0
Mixed
Quarter Revenue
3.3M
-3.9%
vs prior comparable quarter
Net Margin
-20.8%
-7.8 pts
profitability pulse
Free Cash Flow
-786.0K
-8.3%
cash conversion
Net Debt / EBITDA
2.5x
-7.8%
lower is cleaner
Revenue Engine

Latest quarter printed 3.3M with the top line cooling off against the last comparable period.

Profit Stack

Net income landed at -693.0K and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 3.5M while net debt is -3.4M. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q2 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q4 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2025
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
7.5M
Revenue Path
-0.01
EPS / Earnings
Growth cue +0.5%
FY 2027
Consensus
9.0M
Revenue Path
-0.01
EPS / Earnings
Growth cue +0.1%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q3 2025 3.3M -693.0K -786.0K -3.4M
Q1 2025 3.2M -958.0K -193.0K -4.7M
Q3 2024 3.2M -588.0K -540.0K -1.5M
Q1 2024 2.5M -1.4M -1.2M -2.2M
Q3 2023 3.5M -453.0K -857.0K -3.6M
Q1 2023 3.2M -725.0K -705.0K -4.5M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 6.5M -1.7M -2.0M -934.0K
FY 2024 5.8M -2.0M -1.9M -2.2M
FY 2023 6.7M -1.2M -707.0K -1.7M
FY 2022 8.6M 1.0M 1.5M -815.0K
FY 2021 9.2M 1.5M 1.7M -1.5M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend broken

Price is 1.6% through the 52-week range, -10.7% vs 50DMA and -33.4% vs 200DMA. 58.3% of the register is locked by institutions and insiders, leaving 41.7% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend broken Institutional gravity Moderate income rhythm As Of 2026-04-19
Balanced Structure
Structure Score
41.1 / 100
Balanced Structure
Trend Stack
-10.7% / -33.4%
vs 50DMA / 200DMA
52W Position
1.6%
auction position inside the yearly range
Ownership Lock
58.3%
51.0% institutions | 7.4% insiders
Pressure Pocket
41.7% free float
Vendor short-float fields were not supplied
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 7.12 with the stock -10.7% vs 50DMA and -33.4% vs 200DMA. The tape is sitting 1.6% through the 52-week range, which frames the regime as trend broken.

Ownership Register

Institutions hold about 51.0% and insiders about 7.4%, locking roughly 58.3% of the register and leaving 41.7% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
7.12
derived from market cap / shares
52W High
15.00
upper auction edge
52W Low
7.00
lower auction edge
Beta
0.22
volatility character
Shares Out
92.7M
fully diluted count
Shares Float
34.9M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
1:50
2013-09-04

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
40.924
Institutions As Of
2025-05-20
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
2
Sale Director Dealing
1
Purchase TR1
4
Sale TR1
3
Broker Coverage Rows
0
Institution Holders Tracked
4
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for IXI, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-04-21 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
IXICO PLC has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
IXI Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-04-21 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 65.65%
RSI Gauge
Price Change
AI Forecast